Thyroid tumors – moleculargenetic causes and choices for target therapy
Authors:
Běla Bendlová; Šárka Dvořáková; Vlasta Sýkorová; Eliška Václavíková; Tereza Hálková
Authors‘ workplace:
Endokrinologický ústav Praha, Oddělení molekulární endokrinologie
Published in:
Čas. Lék. čes. 2012; 151: 123-127
Category:
Review Articles
Overview
Thyroid tumors are the most common endocrine malignancy. The main genetic changes are point mutations in the RET proto-oncogene (somatic or germ-line) in medullary thyroid carcinoma and point mutations in BRAF and RAS genes or RET/PTC rearrangements in carcinomas developing from follicular cells. Moleculargenetic diagnosis of RET mutations in patients with medullary thyroid carcinoma and their relatives is now the part of clinical approach. Currently, knowledge about genetic causes of thyroid tumors has begun applying into target gene therapy providing new therapeutic drugs and more individualized treatment. This review summarizes main genetic causes of thyroid tumors and their application in target gene therapy.
Key words:
RET, thyroid carcinoma, mutations, gene therapy.
Sources
1. Nikiforov YE, et al. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011; 7: 569–580.
2. Mitsuades N, Fagin JA. Molecular Genetics of Thyroid Cancer: pathogenetic significance and clinical applications. Genetic diagnosis of endocrine disorders 2010; 11: 117–138.
3. Nikiforov YE. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med 2011; 135: 569–577.
4. Hansford JR, et al. Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet 2000; 37: 817–827.
5. Lodish MB, et al. RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer. Expert Rev Anticancer Ther 2008; 8: 625–632.
6. Zitzelsberger H, et al. Molecular rearrangements in papillary thyroid carcinomas. Clin Chim Acta 2010; 411: 301–308.
7. van Veelen W, et al. Medullary thyroid carcinoma and biomarkers: past, present and future. J Intern Med 2009; 266: 126–140.
8. Cakir M, et al. Medullary thyroid cancer: molecular biology and novel molecular therapies. Neuroendocrinology 2009; 90: 323–348.
9. Mulligan LM, et al. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the International RET Mutation Consortium. J Intern Med 1995; 238: 343–346.
10. Raue F, et al. Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management. Hormones (Athens) 2009; 8: 23–28.
11. Dvorakova S, et al. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas. Mol Cell Endocrinol 2008; 284: 21–27.
12. Kloos RT, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009; 19: 565–612.
13. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007; 28: 742–762.
14. Wan PT, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116: 855–867.
15. Sykorova V, et al. BRAFV600E Mutation in the Pathogenesis of a Large Series of Papillary Thyroid Carcinoma in Czech Republic. J Endocrinol Invest 2010; 33: 318–324.
16. Namba H, et al. H-Ras Protooncogene Mutations in Human Thyroid Neoplasms. J Clin Endocrinol Metab 1990: 71: 223–229.
17. Vasko V, et al. Specific Pattern of RAS Oncogene Mutations in Follicular Thyroid Tumors. J Clin Endocrinol Metab 2003; 88: 2745–2752.
18. Moura MM, et al. High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas. J Clin Endocrinol Metab 2011; 96: E863–868.
19. Handkiewicz-Junak D, et al. Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions. Mol Cell Endocrinol 2010; 322: 8–28.
20. Torino F, et al. Medullary thyroid cancer: a promising model for targeted therapy. Curr Mol Med 2010; 10: 608–625.
21. Wells SA Jr, et al. Targeting the RET pathway in thyroid cancer. Clin Cancer Res 2009; 15: 7119–7123.
22. Castellone MD, et al. Receptor tyrosine kinase inhibitors in thyroid cancer. Best Pract Res Clin Endocrinol Metab 2008; 22: 1023–1038.
23. Cerrato A, et al. Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets. J Mol Endocrinol 2009; 43: 143–155.
24. Pinchot SN, et al. Medullary thyroid carcinoma: targeted therapies and future directions. J Oncol 2009; 2009: 183031.
25. Santarpia L, et al. Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma. J Intern Med 2009; 266: 99–113.
26. Wells SA Jr, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010; 28: 767–772.
27. Morabito A, et al. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 2009; 14: 378–390.
28. Pasqualetti G, et al. The emerging role of sunitinib in the treatment of advanced epithelial thyroid cancer: our experience and review of literature. Mini Rev Med Chem 2011; 11: 746–752.
29. Hong D, et al. Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. Mol Cancer Ther 2008; 7: 1001–1006.
30. Duntas LH, et al. Sorafenib: rays of hope in thyroid cancer. Thyroid 2010; 20: 1351–1358.
31. Dienstmann R, et al. BRAF as a target for cancer therapy. Anticancer Agents Med Chem 2011; 11: 285–295.
32. Deshpande HA, et al. Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer. Core Evid 2010; 4: 43–48.
Labels
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain managementArticle was published in
Journal of Czech Physicians
Most read in this issue
- Autophagy and its role in protective and damaging inflammatory response
- Children obesity and its metabolic outcomes
- Thyroid tumors – moleculargenetic causes and choices for target therapy
- Factors influencing the experimentation with smoking: Observed in ELSPAC Study